title: Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques.
abstract: OBJECTIVE
  To investigate the role of exogenous LH in controlled ovarian hyperstimulation for assisted reproductive technologies.
  
  
  METHODS
  Prospective randomized study.
  
  
  METHODS
  SISMER fertility unit.
  
  
  METHODS
  Women showing a hyporesponsiveness to FSH under GnRH agonist down-regulation were randomized into three groups: group A (n = 54) received an increased dosage of FSH; group B (n = 54) was administered recombinant LH in addition to the increased dose of FSH; group C (n = 22) was given additional FSH and LH using hMG as a combined drug. Fifty-four age-matched women with no need to increase the FSH dose were included as a control group (D).
  
  
  METHODS
  None.
  
  
  METHODS
  Implantation and live birth rate per started cycles.
  
  
  RESULTS
  In group B, the pregnancy and implantation rates were statistically higher when compared with groups A and C and did not differ from the control group for normal response. The live birth rate was similar in groups B and D but was half as high in groups A and C.
  
  
  CONCLUSIONS
  Hyporesponsiveness to FSH could be related to iatrogenic LH deficiency that, in turn, could affect oocyte competence. Addition of a small amount of recombinant LH is able to rescue oocyte competence to produce viable embryos.
authors.affiliation: SISMER Reproductive Unit, Bologna, Italy. Annapia.Ferraretti@sismer.it
authors.forename: Anna Pia
authors.initials: AP
authors.lastname: Ferraretti
authors.forename: Luca
authors.initials: L
authors.lastname: Gianaroli
authors.forename: Maria C
authors.initials: MC
authors.lastname: Magli
authors.forename: Arianna
authors.initials: A
authors.lastname: D'angelo
authors.forename: Valeria
authors.initials: V
authors.lastname: Farfalli
authors.forename: Nadia
authors.initials: N
authors.lastname: Montanaro
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D010064:Embryo Implantation; D004624:Embryo Transfer; D005260:Female; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D007986:Luteinizing Hormone / Q000627:therapeutic use*; D010062:Ovulation Induction; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000453:epidemiology; D018873:Pregnancy Rate; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use*; D027724:Reproductive Techniques, Assisted
chemical_list: D011994:Recombinant Proteins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone